Severe mpox in an immunocompromised patient, South Africa 2024
DOI:
https://doi.org/10.7196/SAMJ.2024.v114i10.2407Keywords:
Severe mpox, immunosuppressed, HIV, new outbreakAbstract
-
References
1. De Clercq E, Jiang Y, Li G. Therapeutic strategies for human poxvirus infections: Monkeypox (mpox), smallpox, molluscipox and orf. Travel Med Infect Dis 2023;52:102528. https://doi.org/10.1016/j. tmaid.2022.102528
2. Alakunle E, Kolawole D, Diaz-Canova D, et al. A comprehensive review of monkeypox virus and mpox characteristics. Front Cellular Infect Microbiol 2024:14:1-20. https://doi.org/10.3389/fcimb.2024.1360586 3. Kibungu EM, Vakaniaki EH, Kinganda-Lusamaki E, et al. Clade I-associated mpox cases associated with sexual contact, the Democratic Republic of Congo. Emerg Infect Dis 2024;30(1):172-176. https://
doi.org/10.3201/eid3001.231164
4. Lu J, Xing H, Wang C, et al. Mpox (formerly monkeypox): Pathogenesis, prevention and treatment. Nature 2023:8:458. http://doi.org/10.1038/s41392-023-01675-2
5. Gupta AK, Talukder M, Rosen T, Piguet V. Differential diagnosis, prevention and treatment of mpox (Monkeypox): A review for dermatologists. Am J Clin Derm 2023:24(4):541-556. https://doi. org/10.1007/s40257-023-0078-4
6. Thornhill JP, Barkati S, Walmsey S, et al. Monkeypox virus infection in humans across 16 countries – April - June 2022. N Engl J Med 2022:387(25):e69. http://doi.org/10.1056/NEJMc2213969
7. Fink DL, Callaby H, Luintel A, et al. Clinical features and management of individuals admitted to hospital with monkeypox and associated complications across the UK: A retrospective cohort study. Lancet Infect Dis 2023;23(5):589-597.http://doi.org/10.1016/S1473-3099(22)00806-4
8. South African Government. Minister Joe Phaahla on outbreak of Mpox disease in South Africa and efforts to curb the spread. 12 June 2024. https://www.gov.za/news/media-statements/minister-joe- phaahla-outbreak-mpox-disease-south-africa (accessed 12 June 2024).
9. Zeng Y, Liu X, Li Y, et al.The assessment on cross immunity with smallpox virus and antiviral drug sensitivity of the isolated mpox virus strain WIBP-MPXV-001 in China. Emerg Microbes Infect 2023;12(1):2208682. http://doi.org/10.1080/22221751.2023.2208682
10. Mitja O, Alemany A, Marks M, et al. Mpox in people with advanced HIV infection: A global case series. Lancet 2023;401(10380):939-949. http://doi.org/10.1016/S0140-6736(23)00273-8
11. Moltrasio C, Boggio FL, Romagnuolo M, et al. Monkeypox: A histopathological and transmission electron microscopy study. Microorganisms 2023;11(7):1781.
12. Chalali F, Merlant M, Truong A, et al. Histological features associated with human mpox virus infection in 2022 outbreak in a nonendemic country. Clin Infect Dis 2023;76(6):1132-1135. http://doi. org/10.3390/microorganisms11071781
13. National Institute of Communicable Diseases. Multi-country mpox outbreak. May 2024. https://nicd. ac.za/wp-content/uploads/2024/05/BEYOND-OUR-BORDERS-Mpox-Outbreak-May-2024_1.pdf (accessed 30 May 2024).
14. WorldHealthOrganization.Clinicalmanagementandinfectionpreventionandcontrolformonkeypox: Interim rapid response guidance. Geneva: WHO, 10 June 2022. https://www.who.int/publications/i/item/ WHO-MPX-Clinical-and-IPC-2022.1 accessed 11 June 2024 (accessed 11 June 2024).
15. Hoy SM. Tecovirimat: First global approval. Drugs 2018;78(13):1377-1382. http://doi.org/10.1007/ s40265-018-0967-6
16. World Health Organization. Strategic framework for enhancing prevention and control of mpox 2024 - 2027. Geneva: WHO, May 2024. https://www.who.int/publications/i/item/9789240092907 (accessed 11 June 2024).
17. Centers for Disease Control. Recommendations for use of Jynneos vaccine. CDC, 13 June 2024.
https://www.cdc.gov/poxvirus/mpox/interim-considerations/overview.html#recommendations
(accessed 19 June 2024).
Downloads
Published
Issue
Section
License
Copyright (c) 2024 E Vardas, M Naidoo, N A I Chopdat, J Weyer, A I Ranchod, L Moosa, A J Glass, L H Blumberg , J Elskie, W Garyson , T Pitjadi , Z Kalla
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.